SweetSpot - Die Auswirkung nicht-nährstoffreicher Süßstoffe auf die Gesundheit
SweetSpot - Die Wirkung nicht-nutritiver Süßstoffe auf die Glukoseregulation, das Darmmikrobiom und die Darmhormonsekretion bei gesunden Erwachsenen: eine vollständig kontrollierte Cross-over-Interventionsstudie
The aim of the study is to investigate the effect of non-nutritive sweeteners on glucose regulation. Secondary objectives are to investigate the effect of NNS on gut microbiome, gut hormone secretion, sweet taste sensitivity and preference, and the excretion of NNS in urine.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Sugar intake has increased over the years, simultaneously with the prevalence of overweight and obesity. To decrease sugar intake, consumption of non-nutritive sweeteners (NNS) has increased and opinions on its use remain divided. A fully controlled dietary intervention using a NNS mixture and dose that is similar to real-life intake, is therefore necessary to advance our understanding of the potential effects of NNS on glucose regulation, gut microbiome, and gut hormone secretion under real-life conditions.
The aim of this study is to investigate the effect of non-nutritive sweeteners on glucose regulation. Secondary objectives are to investigate the effect of NNS on gut microbiome, gut hormone secretion, sweet taste sensitivity and preference, and the excretion of NNS in urine.
To do this, a single blind, fully controlled dietary intervention with a cross-over design will be performed. The study will consist of 2x8 weeks of intervention, with a washout of > 6 weeks in between. The study population will be 60 healthy adults aged 45-79, with a BMI between 20-35 kg/m2.
The study will consist of a fully controlled diet of two 8-week intervention periods (2 weeks run-in + 6 weeks intervention). The diets differ in the presence of non-nutritive sweeteners (NNS): NNS-diet versus non-NNS diet, where additional NNS are added to the NNS-diet.
The primary outcome measure will be the within person difference in blood glucose incremental area under the curve following a 75 g glucose tolerance test between the NNS diet and the non-NNS diet. Secondary outcome measures are the effect of NNS on Matsuda index, insulin response, blood lipid profile, and gut hormone secretion will be determined. The effect of NNS on small- and large intestinal microbiome will be investigated by a change in composition, functionality, and short chain fatty acid content. The effect of NNS on sweet taste sensitivity, preference, and liking will be investigated, as well as the excretion of NNS in urine and saliva.
The total time invested by participants is around 85 hours. Participants are restricted for 16 weeks in their eating habits, since they follow a fully controlled diet prepared by the research facility. Participants will visit the research facility in total 38 times. In total, ~ 603 mL of blood will be drawn by experienced nurses over the entire RCT (>6 month period). During DEXA scans, participants will receive a total of about 0.006 mSv of radiation.
Invasive measurements that participants can experience as burden are collection of faecal and urine samples, and finding back the Simba capsules in the stool. Non-invasive measurements for participants are wearing the CGM, wearing the ActiGraph, consuming the blue cakes, and performing sensory tests.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Gelderland
-
Wageningen, Gelderland, Niederlande, 6708WG
- Wageningen University & Research
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age 45-79 years;
- BMI of 20-35 kg/m2;
- Having veins suitable for placement of a venflon catheter.
Exclusion Criteria:
- Diseases or prior surgeries affecting the stomach, liver, kidneys or intestines (allowed i.e. appendectomy);
- Cardiovascular diseases (e.g. heart failure) or cancer (e.g. non-invasive skin cancer allowed);
- Diagnosed with type 1 or type 2 diabetes;
- Drug treated thyroid diseases (well substituted hypothyroidism is allowed for inclusion);
- HbA1c level >6.5% (>48 mmol/mol), as measured during the screening visit;
- Anaemia defined as Hb concentrations <8.5 mmol/L for men and <7.5 mmol/L for women via finger prick;
- Regular use of/receiving medication interfering with research outcomes (as judged by research physician), such as use of glucose lowering drugs, insulin, or use of medication that impacts the gastro-intestinal system;
- Use of antibiotics over the last 3 months before study start;
- Donated blood within 2 months prior to the screening;
- Food allergies, intolerances (including lactose/gluten intolerance) for products used in the study design and/or dietary restrictions interfering with the study (including special diets and eating disorders);
- Followed a diet that can interfere with the study outcomes within 1 month prior to the screening (e.g. ketogenic, sugar free, carbohydrate free);
- Not willing to eat all products in the study diet, including eggs and dairy. Vegetarian is possible;
- Not willing to consume non-nutritive sweeteners;
- Not willing to quit the use of supplements that can interfere with the study outcomes (e.g. pre- or probiotics).
- Intention to change the intensity of exercise during the study period or planning to join a intensive sport event (e.g. marathon or triathlon);
- Intention to lose or gain weight;
- Working night shifts regularly;
- Smoking regularly
- Use of soft and/or hard drugs (cannabis included);
- Abuse of alcohol (defined as >14 glasses (women) or >21 glasses (men) of alcoholic beverages per week);
- Being pregnant or lactating or planning to become pregnant;
- Inability to understand study information and/or communicate with staff;
- Participation in another study that involves an intervention within two months prior to the intervention;
- Working or doing a thesis/internship at the division of Human Nutrition & Health, or the Food, Health & Consumer Research group of Wageningen Food & Biobased Research.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Sonstiges: NNS / no-NNS
In this arm, participants will first receive the NNS diet, and the no-NNS diet in the second study period. |
Fully controlled diet with added mixture of non-nutritive sweeteners. The mixture consist of 6 different non-nutritive sweeteners: acesulfame-K, aspartame, cyclamate, saccharin, sucralose, and rebaudioside A (stevia). Fully controlled diet without any non-nutritive sweeteners added. |
|
Sonstiges: No-NNS / NNS
In this arm, participants will first receive the no-NNS diet, and the NNS diet in the second study period. |
Fully controlled diet with added mixture of non-nutritive sweeteners. The mixture consist of 6 different non-nutritive sweeteners: acesulfame-K, aspartame, cyclamate, saccharin, sucralose, and rebaudioside A (stevia). Fully controlled diet without any non-nutritive sweeteners added. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Difference in change in 2h iAUC glucose after 6 weeks between the intervention and the control.
Zeitfenster: Week 2 and week 8 in both intervention periods (4 times in total)
|
The primary outcome measure is the difference in change in iAUC of blood glucose levels following a 2-hour oral glucose tolerance test (OGTT) after six weeks between the intervention period and the control period. |
Week 2 and week 8 in both intervention periods (4 times in total)
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Matsuda index
Zeitfenster: Week 2 and week 8 in both intervention periods (4 times in total)
|
Matsuda index after an OGTT |
Week 2 and week 8 in both intervention periods (4 times in total)
|
|
Fasting blood glucose
Zeitfenster: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Fasting blood glucose |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Fasting blood insulin
Zeitfenster: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Fasting blood insulin |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Postprandial insulin response
Zeitfenster: Week 2 and 8 in both intervention periods (4 times in total).
|
2-hour iAUC blood insulin during OGTT |
Week 2 and 8 in both intervention periods (4 times in total).
|
|
Postprandial glucose response after a breakfast
Zeitfenster: Week 7 in both study periods (2 times in total)
|
Postprandial blood glucose responses (PPGR) following specific meals measured by CGM. |
Week 7 in both study periods (2 times in total)
|
|
Blood lipid profile
Zeitfenster: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
All circulating blood lipids, including all cholesterol types, triglycerides, and free fatty acids (FFAs). |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Gut microbiota composition
Zeitfenster: Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
|
Microbiota composition in faeces |
Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
|
|
Gut microbiota function
Zeitfenster: Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
|
Microbiota functionality measured in faeces |
Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
|
|
Microbial metabolites
Zeitfenster: Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
|
Microbial metabolites measured in faeces |
Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
|
|
Small intestinal microbiota composition
Zeitfenster: Week 7 of both intervention periods (2 times in total).
|
Microbiota composition of the small intestine measured with Simba Capsules |
Week 7 of both intervention periods (2 times in total).
|
|
Gastro-intestinal transit time
Zeitfenster: Baseline & week 7 of both intervention periods (3 times in total).
|
Gastro-intestinal transit time measured with blue muffins. |
Baseline & week 7 of both intervention periods (3 times in total).
|
|
Oral microbiome composition & function
Zeitfenster: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Oral microbiome composition & function measured in saliva |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Postprandial GLP-1 secretion
Zeitfenster: Week 2 and 8 of both intervention periods (4 times in total).
|
3-hour AUC of GLP-1 during an OGTT. |
Week 2 and 8 of both intervention periods (4 times in total).
|
|
Postprandial GIP secretion
Zeitfenster: Week 2 and 8 of both intervention periods (4 times in total).
|
3-hour AUC of GIP during an OGTT. |
Week 2 and 8 of both intervention periods (4 times in total).
|
|
Sweetness-liker phenotype
Zeitfenster: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Sweetness-liker phenotype, with the sweetness liker test. |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Sweetness preference & liking
Zeitfenster: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Sweetness preference & liking measured on a rank-rating scale. Preference will be determined using the categorical values from the rank-rating scale (1-5), and liking will be determined using the continuous values from the rank-rating scale (0-100). |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Sweet taste sensitivity
Zeitfenster: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Sweet taste sensitivity measured on a 100mm Visual Analogue Scale. A higher score for all solutions indicates a higher sweet taste sensitivity. |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Excretion of NNS in urine
Zeitfenster: Baseline, week 2 and week 8 in intervention period 1, and every two weeks in intervention period 2 (7 times in total).
|
Excretion of NNS in urine |
Baseline, week 2 and week 8 in intervention period 1, and every two weeks in intervention period 2 (7 times in total).
|
|
Excretion of NNS in saliva
Zeitfenster: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Excretion of NNS in saliva |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Anthropometrics
Zeitfenster: Baseline
|
Measured as weight (kg), height (m), waist circumference (cm), and hip circumference (cm). Weight and height will be combined to report BMI in kg/m^2. |
Baseline
|
|
Body composition
Zeitfenster: Baseline & week 8 of both intervention periods (3 times in total).
|
Body composition as measured by DEXA (Dual Energy X-ray Absorptiometry). |
Baseline & week 8 of both intervention periods (3 times in total).
|
|
Habitual food intake
Zeitfenster: Baseline
|
Habitual dietary intake assessment with a food frequency questionnaire (FFQ). |
Baseline
|
|
Physical activity level
Zeitfenster: Baseline.
|
Physical activity level by the Short Questionnaire to Assess Health-enhancing physical activity (SQUASH). |
Baseline.
|
|
Habitual NNS consumption
Zeitfenster: Baseline
|
Habitual NNS consumption by questionnaire |
Baseline
|
|
Gastro-intestinal symptoms
Zeitfenster: Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
|
Gastro-intestinal symptoms by GSRS questionnaire. |
Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
|
|
Satiety
Zeitfenster: Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
|
Satiety questionnaire, adapted from the Control of Eating Questionnaire. |
Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
|
|
Genetic variation
Zeitfenster: Baseline
|
Single Nucleotide Polymorphisms (SNPs) in genes relevant collected using buffycoat. |
Baseline
|
|
Taste function
Zeitfenster: Baseline
|
Measure the ability to recognize the basic tastes in different concentrations, assessed with validated Taste Strips. |
Baseline
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- NL010297
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .